Gemcitabine plus taxane combinations in non-small cell lung cancer

Semin Oncol. 1999 Feb;26(1 Suppl 4):19-24.

Abstract

Among the relatively new cytotoxic agents that are active in non-small cell lung cancer, gemcitabine and the taxanes (paclitaxel and docetaxel) are certainly of particular interest due to their essentially nonoverlapping toxicities and single-agent activities, which compare favorably with single-agent cisplatin. For these reasons, new combinations including these agents are being tested in dose-finding studies in phase II and III trials. Combinations of gemcitabine with a taxane, with or without a platinum compound, represent new and promising regimens for the treatment of non-small cell lung cancer and other tumor types.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Clinical Trials as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Paclitaxel / administration & dosage*
  • Platinum Compounds / administration & dosage

Substances

  • Platinum Compounds
  • Deoxycytidine
  • gemcitabine
  • Paclitaxel